The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to ...

Eli Lilly is building out its gene therapy pipeline for hearing loss through a new deal with RNA-focused startup Rznomics.

Genie®, a leading innovator in garage door openers and home security products, proudly announces the release of its newest innovation: a residential linear actuator gate operator designed for ...

Today the Coroner's Office tabled its inquest report on the tragic death of Mr. Raphaël André, Innu from the community of Matimekush?Lac-John, in Montréal on January 17, 2023. The Assembly of First ...

Rebrain SAS's Optimmri platform received European Medical Device Regulation CE mark certification to enable surgeons to ...

Eli Lilly liet zondag weten dat zijn geneesmiddel Zepbound 47 procent meer gewichtsverlies oplevert dan Wegovy van Novo ...